Notably, a significant increase in both the number and proportion of CD36+CD8+ T cells in patients with more advanced stage (p < 0.001), larger tumor size (p < 0.01), and lymph node metastasis (p < 0.0001) was observed, but the number and proportion of CD36+CD8+ T cells in patents with or without EGFR mutation had no significant difference (Fig. 2F and G). This evidence concerns the gene CD8A and metastatic malignant neoplasm in the lymph nodes.